RIGEL PHARMACEUTICALS INC
RIGLDrugs in Pipeline
14
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
RIGL Earnings Report
EPS Est: $0.91 | FQ end 2026-06 | Call: 2026-08-04 15:00:00
R906289 Monosodium (R289 Na) Phase 2 Est. Readout
Primary completion for R906289 Monosodium (R289 Na) trial (NCT05308264) in Low Risk Myelodysplastic Syndromes
SourceHow RIGL's past catalysts played out
Fostamatinib disodium
Immune Thrombocytopenic Purpura
fostamatinib
Lymphoma
Fostamatinib 150 mg
IGA Nephropathy
Fostamatinib 150 mg bid
Warm Antibody Autoimmune Hemolytic Anemia
Fostamatinib disodium (R935788)
Rheumatoid Arthritis
R906289 Monosodium (R289 Na)
Low Risk Myelodysplastic Syndromes
R940343 1mg
Asthma
R348 Ophthalmic Solution, 0.2%
Keratoconjunctivitis Sicca
Olutasidenib + TMZ
High Grade Glioma
R932333
Lupus Erythematosus, Discoid
R348 Ophthalmic Solution, 0.5%
Chronic Graft-versus-host Disease
Fostamatinib Disodium / R935788
Purpura, Thrombocytopenic, Idiopathic
R926112
Rhinitis, Allergic, Seasonal
R788
Rheumatoid Arthritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fostamatinib disodium | Phase 3 | Immune Thrombocytopenic Purpura | - | - |
fostamatinib | Phase 3 | Lymphoma | - | - |
Fostamatinib 150 mg | Phase 2 | IGA Nephropathy | - | - |
Fostamatinib 150 mg bid | Phase 2 | Warm Antibody Autoimmune Hemolytic Anemia | - | - |
Fostamatinib disodium (R935788) | Phase 2 | Rheumatoid Arthritis | - | - |
R906289 Monosodium (R289 Na) | Phase 2 | Low Risk Myelodysplastic Syndromes | - | - |
R940343 1mg | Phase 2 | Asthma | - | - |
R348 Ophthalmic Solution, 0.2% | Phase 2 | Keratoconjunctivitis Sicca | - | - |
Olutasidenib + TMZ | Phase 2 | High Grade Glioma | - | - |
R932333 | Phase 2 | Lupus Erythematosus, Discoid | - | - |
R348 Ophthalmic Solution, 0.5% | Phase 2 | Chronic Graft-versus-host Disease | - | - |
Fostamatinib Disodium / R935788 | Phase 2 | Purpura, Thrombocytopenic, Idiopathic | - | - |
R926112 | Phase 2 | Rhinitis, Allergic, Seasonal | - | - |
R788 | Phase 2 | Rheumatoid Arthritis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in RIGEL PHARMACEUTICALS INC's drug pipeline?→
CatalystAlert tracks 14 drug candidates in RIGEL PHARMACEUTICALS INC's (RIGL) pipeline across Phase 3, Phase 2. Its lead program is Fostamatinib disodium (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is RIGEL PHARMACEUTICALS INC's next FDA catalyst?→
RIGEL PHARMACEUTICALS INC's (RIGL) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RIGL biotech catalysts?→
Add RIGL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow RIGEL PHARMACEUTICALS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.